



US008945621B2

(12) **United States Patent**
Ault et al.

(10) **Patent No.:** **US 8,945,621 B2**
(45) **Date of Patent:** **Feb. 3, 2015**

(54) **METHOD FOR TREATING A PATIENT AT RISK FOR DEVELOPING AN NSAID-ASSOCIATED ULCER**

(75) Inventors: **Brian Ault**, Wilmington, DE (US);
Clara Hwang, Wilmington, DE (US);
Everardus Orlemans, Chapel Hill, NC (US);
John R Plachetka, Chapel Hill, NC (US);
Mark Sostek, Wilmington, DE (US)

(73) Assignees: **Pozen Inc.**, Chapel Hill, NC (US);
Horizon Pharma USA, Inc., Deerfield, IL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 480 days.

(21) Appl. No.: **12/822,612**

(22) Filed: **Jun. 24, 2010**

(65) **Prior Publication Data**
US 2010/0330179 A1 Dec. 30, 2010

Related U.S. Application Data

(60) Provisional application No. 61/220,420, filed on Jun. 25, 2009, provisional application No. 61/225,970, filed on Jul. 16, 2009, provisional application No. 61/310,525, filed on Mar. 4, 2010.

(51) **Int. Cl.**
A61K 9/24 (2006.01)
A61K 31/192 (2006.01)
A61K 31/4439 (2006.01)
A61K 45/06 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 31/192** (2013.01); **A61K 9/209** (2013.01); **A61K 31/4439** (2013.01); **A61K 45/06** (2013.01)
USPC **424/472**

(58) **Field of Classification Search**
USPC 424/472
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

- 4,198,390 A 4/1980 Rider
- 4,255,431 A 3/1981 Junggren et al.
- 4,344,929 A 8/1982 Bensen et al.
- 4,508,905 A 4/1985 Junggren et al.
- 4,554,276 A 11/1985 LaMattina
- 4,562,261 A 12/1985 Hirata et al.
- 4,619,934 A 10/1986 Sunshine et al.
- 4,676,984 A 6/1987 Wu et al.
- 4,704,278 A 11/1987 Wu et al.
- 4,726,951 A 2/1988 Panoz et al.
- 4,738,974 A 4/1988 Brandstrom
- 4,757,060 A 7/1988 Lukacsko et al.
- 4,758,579 A 7/1988 Kohl et al.
- 4,766,117 A 8/1988 Crawford et al.

- 4,865,847 A 9/1989 Gosswein
- 4,948,581 A 8/1990 Sawayanagi et al.
- 4,965,065 A 10/1990 Lukacsko et al.
- 5,026,560 A 6/1991 Makino et al.
- 5,035,899 A 7/1991 Saeki et al.
- 5,037,815 A 8/1991 Lukacsko et al.
- 5,043,358 A 8/1991 Lukacsko et al.
- 5,051,262 A 9/1991 Panoz et al.
- 5,093,132 A 3/1992 Makino et al.
- 5,204,118 A 4/1993 Goldman et al.
- 5,260,333 A 11/1993 Lukacsko et al.
- 5,364,616 A 11/1994 Singer et al.
- 5,373,022 A 12/1994 Fawzi et al.
- 5,409,709 A 4/1995 Ozawa et al.
- 5,417,980 A 5/1995 Goldman et al.
- 5,466,436 A 11/1995 Stables
- 5,514,663 A 5/1996 Mandel
- 5,601,843 A 2/1997 Gimet et al.
- 5,631,022 A 5/1997 Mandel et al.
- 5,643,960 A 7/1997 Breitner et al.
- 5,667,802 A 9/1997 Grimberg
- 5,679,376 A 10/1997 Stevens et al.
- 5,686,105 A 11/1997 Kelm et al.
- 5,690,960 A 11/1997 Bengtsson et al. 424/480
- 5,702,723 A 12/1997 Griffin
- 5,714,504 A 2/1998 Lindberg et al.
- 5,716,648 A 2/1998 Halskov et al.
- 5,750,531 A 5/1998 Lee et al.
- 5,817,338 A 10/1998 Bergstrand et al.
- 5,817,340 A 10/1998 Roche et al.

(Continued)

FOREIGN PATENT DOCUMENTS

- AU 2006235929 11/2006
- CA 2139653 12/1994

(Continued)

OTHER PUBLICATIONS

- Abelo et al., "Pharmacodynamic modeling of reversible gastric acid pump inhibition in dog and man," *European Journal of Pharmaceutical Sciences*, 14, pp. 339-346 (2001).
- Alexander, et al., "Pilot Evaluation of a Novel Combination Tablet (PN 400) Containing a Proton Pump Inhibitor and a Nonsteroidal Anti-Inflammatory Drug in Prevention of Upper Gastrointestinal Mucosal Injury," *American Journal of Gastroenterology*, 100(9), p. S68, 135 (2005).
- Andersson, "Pharmacokinetics, metabolism and interactions of acid pump inhibitors," *Clin. Pharmacokinet.* 31(1)9-28 (Jul. 1996).
- Anonymous: "A 12-month, phase 3, open-label, multi-center study to evaluate the long-term safety of PN 400" Internet article (Sep. 11, 2007), XP002553437, retrieved from the internet, URL:<http://clinicaltrials.gov/show/NCT00527904>>.

(Continued)

Primary Examiner — Adam C Milligan
(74) *Attorney, Agent, or Firm* — Parker Highlander PLLC

(57) **ABSTRACT**

The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer.

(56)

References Cited

U.S. PATENT DOCUMENTS

5,840,737 A 11/1998 Phillips
 5,872,145 A 2/1999 Plachetka 514/415
 5,900,424 A 5/1999 Kallstrom et al.
 5,955,451 A 9/1999 Lichtenberger et al.
 6,013,281 A 1/2000 Lundberg et al.
 6,025,395 A 2/2000 Breitner et al.
 6,060,499 A 5/2000 Plachetka 514/415
 6,093,734 A 7/2000 Garst et al.
 6,126,816 A 10/2000 Ruiz, Jr. 210/95
 6,132,768 A 10/2000 Sachs et al.
 6,132,771 A 10/2000 Depui et al.
 6,136,344 A 10/2000 Depui et al.
 6,160,020 A 12/2000 Ohannesian et al.
 6,162,816 A 12/2000 Bohlin et al.
 6,183,776 B1 2/2001 Depui et al.
 6,183,779 B1 2/2001 Ouali et al.
 6,207,188 B1 3/2001 Gustavsson et al.
 6,231,888 B1 5/2001 Lerner et al.
 6,287,600 B1 9/2001 Ouali et al.
 6,365,184 B1 4/2002 Depui et al.
 6,369,085 B1 4/2002 Cotton et al.
 6,372,255 B1 4/2002 Saslawski et al.
 6,387,410 B1 5/2002 Woolfe et al.
 6,395,298 B1 5/2002 Flanagan et al.
 6,428,810 B1 8/2002 Bergstrand et al.
 6,485,747 B1 11/2002 Flanagan et al.
 6,489,346 B1 12/2002 Phillips
 6,544,556 B1 4/2003 Chen et al.
 6,599,529 B1 7/2003 Skinhoj et al.
 6,610,323 B1 8/2003 Lundberg et al.
 6,613,354 B2 9/2003 Depui et al.
 6,632,451 B2 10/2003 Penhasi et al.
 6,641,838 B2 11/2003 Pather et al.
 6,645,988 B2 11/2003 Phillips
 6,673,819 B2 1/2004 Bergman et al.
 6,685,964 B1 2/2004 Bartholomaeus et al.
 6,699,885 B2 3/2004 Phillips
 6,713,089 B1 3/2004 Bertelsen et al.
 6,749,867 B2 6/2004 Robinson et al.
 6,780,882 B2 8/2004 Phillips
 6,787,164 B2 9/2004 Gelber et al.
 6,797,283 B1 9/2004 Edgren et al.
 6,869,615 B2 3/2005 Chen et al.
 6,875,872 B1 4/2005 Lindberg et al.
 6,926,907 B2 8/2005 Plachetka
 7,029,701 B2 4/2006 Chen
 7,030,162 B2 4/2006 Plachetka et al. 514/619
 7,060,694 B2 6/2006 Plachetka et al. 514/177
 7,094,425 B2 8/2006 Scott et al.
 7,332,183 B2 2/2008 Plachetka et al. 424/472
 7,399,772 B2 7/2008 Phillips
 7,411,070 B2 8/2008 Cotton et al.
 7,488,497 B2 2/2009 Depui et al.
 7,745,466 B2 6/2010 Cotton et al.
 7,785,626 B2 8/2010 Pettersson et al.
 7,846,914 B2 12/2010 Petrus
 8,206,741 B2 6/2012 Plachetka
 2001/0025107 A1 9/2001 Barberich et al.
 2001/0036473 A1 11/2001 Scott et al. 424/463
 2001/0044410 A1 11/2001 Gelber et al. 514/27
 2002/0012676 A1 1/2002 Lundberg et al.
 2002/0042433 A1 4/2002 Yelle et al.
 2002/0044962 A1 4/2002 Cherukuri et al.
 2002/0045184 A1 4/2002 Chen
 2002/0086029 A1 7/2002 Lundberg et al.
 2002/0090395 A1 7/2002 Woolfe et al.
 2002/0111370 A1 8/2002 Bergman et al. 514/338
 2002/0155153 A1 10/2002 Depui et al. 424/452
 2002/0160046 A1 10/2002 Robinson et al. 424/469
 2003/0008903 A1 1/2003 Barberich et al.
 2003/0040537 A1 2/2003 Plachetka et al. 514/406
 2003/0113375 A1 6/2003 Lundberg et al.
 2003/0129235 A1 7/2003 Chen et al. 424/470

2003/0232876 A1 12/2003 Plachetka 514/419
 2004/0022846 A1 2/2004 Depui et al. 424/452
 2004/0048896 A1 3/2004 Phillips
 2004/0121004 A1 6/2004 Taneja
 2004/0131676 A1 7/2004 Taneja
 2004/0171646 A1 9/2004 Phillips
 2004/0180089 A1 9/2004 Plachetka et al. 424/4
 2005/0004171 A1 1/2005 Phillips
 2005/0042304 A1 2/2005 Phillips
 2005/0054682 A1 3/2005 Phillips
 2005/0147668 A1 7/2005 Bertelsen et al.
 2005/0163847 A1 7/2005 Cheng et al.
 2005/0227949 A1 10/2005 Edalatpour
 2005/0249806 A1 11/2005 Proehl et al.
 2005/0249811 A1 11/2005 Plachetka 424/472
 2006/0165797 A1 7/2006 Plachetka
 2006/0177504 A1 8/2006 Sundharadas 424/488
 2006/0178348 A1 8/2006 Plachetka
 2006/0178349 A1 8/2006 Plachetka
 2006/0287284 A1 12/2006 Schutze et al.
 2007/0122470 A1 5/2007 Johansson et al.
 2007/0154542 A1 7/2007 Tananbaum et al.
 2007/0184078 A1 8/2007 Chen
 2007/0207200 A1 9/2007 Plachetka et al. 424/451
 2007/0237820 A1 10/2007 Cheng et al.
 2007/0243251 A1 10/2007 Taneja
 2008/0031941 A1 2/2008 Pettersson
 2008/0031950 A1 2/2008 Sessa
 2008/0103169 A1 5/2008 Phillips
 2009/0074863 A1 3/2009 Taneja
 2009/0075950 A1 3/2009 Taneja
 2009/0297594 A1 12/2009 Depui et al. 424/451
 2010/0062064 A1 3/2010 Ault et al.
 2010/0172983 A1 7/2010 Plachetka
 2010/0178334 A1 7/2010 Johansson et al.
 2012/0064156 A1 3/2012 Plachetka

FOREIGN PATENT DOCUMENTS

DE 4035455 5/1992
 DE 19801811 12/2004
 EP 0 005 129 A1 10/1979
 EP 0005129 4/1981
 EP 0 124 495 A2 11/1984
 EP 0 166 287 A1 1/1986
 EP 0 167 958 A2 1/1986
 EP 0 174 726 A1 3/1986
 EP 0124495 1/1987
 EP 0 244 380 A2 11/1987
 EP 0 244 380 B1 11/1987
 EP 0174726 4/1989
 EP 0320550 6/1989
 EP 0320551 6/1989
 EP 0166287 8/1989
 EP 0167958 1/1991
 EP 0 426 479 A1 5/1991
 EP 0244380 1/1993
 EP 0 550 083 A1 7/1993
 EP 0426479 2/1994
 EP 0550083 3/1999
 EP 1 020 461 A2 7/2000
 EP 1 068 867 A2 1/2001
 EP 1068867 9/2003
 EP 1726300 11/2006
 EP 1726301 11/2006
 EP 1020461 7/2009
 GB 2105193 3/1983
 GB 2163747 3/1986
 GB 2216413 10/1989
 JP 2005-145894 6/2005
 WO 8503443 8/1985
 WO 9006925 6/1990
 WO 9116886 11/1991
 WO 9116895 11/1991
 WO 9116896 11/1991
 WO 9119711 12/1991
 WO 9119712 12/1991

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	9407541	4/1994
WO	9427988	12/1994
WO	9501977	1/1995
WO	9532959	12/1995
WO	9605177	2/1996
WO	9605199	2/1996
WO	9614839	5/1996
WO	9622780	8/1996
WO	9711701	4/1997
WO	9725064	7/1997
WO	9813073	4/1998
WO	9822117	5/1998
WO	9822118	5/1998
WO	9854171	12/1998
WO	9900380	1/1999
WO	9912524	3/1999
WO	9929320	6/1999
WO	9966919	12/1999
WO	0001368	1/2000
WO	0015195	3/2000
WO	0056339	9/2000
WO	0071122	11/2000
WO	0072838	12/2000
WO	0078293	12/2000
WO	0124777	4/2001
WO	0166088	9/2001
WO	0222108	3/2002
WO	02066002	8/2002
WO	WO 02/098352	12/2002
WO	03017980	3/2003
WO	2004062552	7/2004
WO	2004064815	8/2004
WO	2005074536	8/2005
WO	2005074930	8/2005
WO	2006044202	4/2006
WO	2007064274	6/2007
WO	2007078874	7/2007
WO	2008101060	8/2008
WO	2009012393	1/2009
WO	2009145905	12/2009
WO	2010151697	12/2010

OTHER PUBLICATIONS

Anonymous: "PK Study to evaluate Esomeprazole plasma levels following the administration of PN 400" Internet article (Feb. 11, 2008), XP002553435, retrieved from the internet: URL:<http://clinicaltrials.gov/show/NCT00599404>>.

Anonymous: "Study evaluating the bioavailability of Naproxen 500 mg in three formulations," Internet article (May 11, 2008), XP002553436m retrieved from the internet: URL:<http://clinicaltrials.gov/show/NCT00665743>>.

Arthrotec Data sheet (Aug. 2009).

Awtry, et al., "Aspirin," *Circulation* 101:1206-1218 (2000).

Ballinger, et al., "COX-2 Inhibitors vs. NSAIDs in Gastrointestinal Damage and Prevention," *Exp. Opin. Pharmacother.* 2(1):31-40 (2001).

Barnett et al., "Effects of SCH 32651 on resting and stimulated acid secretion in guinea-pig isolated fundic mucosa," *Br. J. Pharmacol.*, 83, pp. 75-82 (1984).

Berardi et al., "Elevation of Gastric pH with Ranitidine does not affect the release characteristics of sustained release Ibuprofen tablets," *Biopharmaceutics & Drug Disposition*, 9: pp. 337-347 (1988).

Bergmann et al., "Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses," *Clin. Pharmacol. Ther.*, 52, pp. 413-416 (Oct. 1992).

Bianchi Porro et al., "Pantoprazole vs placebo in prevention of NSAID-induced ulcers," *Gastroenterology*, 114(4), p. A74 (1998).

Bianchi Porro, et al., "Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A

Bianchi Porro, et al., "Why Are Non-Steroidal Anti-Inflammatory Drugs Important in Peptic Ulcers?" *Aliment. Pharmacol. Therap.*, 1, pp. 540S-547S (1987).

Bigard English translation—Bigard, et al. "Effet protecteur de l'omeprazole sur les lesions gastriques induites par une prise unique d'aspirine chez l'homme," *Gastroenterol. Clin. Biol.*, 12, pp. 770-771 (1998).

Bigard et al., "Complete prevention by omeprazole of aspirin induced gastric lesions in healthy subjects," *Gut*, 29(5), p. A712, T49 (1988).

Bigard et al., "Effet protecteur de l'omeprazole sur les lesions gastriques induites par une prise unique d'aspirine chez l'homme," *Gastroenterol. Clin. Biol.*, 12, pp. 770-771 (1998).

Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," *N. Engl. J. Med.*, 343, pp. 1520-1528 (2000).

Brown et al., "Prevention of the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs," *Pract. Drug Safety*, 21, pp. 503-512 (1999).

Brown, et al., "Asprin- and Indomethacin-Induced Ulcers and Their Antagonism by Antihistamines," *Euro. J. Pharm.*, 51, pp. 275-283 (1978).

Byrn et al., "Pharmaceutical solids: A strategic approach to regulatory considerations," *Pharm. Res.*, 12(7), pp. 945-954 (1995).

Carrasco-Portugal, et al., "Bioavailability of a Formulation Containing a Diclofenac-Ranitidine Combination," *Proc. West. Pharmacol. Soc.*, 45, pp. 8-10 (2002).

Chan et al., "Eradication of *H. pylori* versus maintenance acid suppression to prevent recurrent ulcer hemorrhage in high risk NSAID users: A prospective randomized study," *Gastroenterology*, 114, p. A87, G0356 (1998).

Chan, et al., "Clopidogrel versus Aspirin and Esomeprazole to prevent recurrent ulcer bleeding," *New Eng. J. Med.* 352, pp. 238-244 (2005).

Chandramouli et al., *J. Pharmaceutical Pain and Symptom Control*, pp. 27-40 (2000).

Chang et al., "Polymethacrylates," *Handbook of Pharmaceutical Excipients*, Fifth Edition, Ed. Raymond C. Rowe, Paul J. Sheskey and Sian C. Owen, London: Pharmaceutical Press, pp. 553-560 (2006).

Cullen et al., "Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users," *Aliment. Pharmacol. Ther.*, 12, pp. 135-140 (1998).

Dajani, Esam Z., "Perspective on the Gastric Antisecretory Effects of Misoprostol in Man," *Prostaglandins*, 33, pp. 68-77 (1987).

Daneshmend et al., "Abolition by omeprazole of aspirin-induced gastric mucosal injury in man," *Gut*, 31, pp. 514-517 (1990).

Daneshmend et al., "Use of microbleeding and an ultrathin endoscope to assess gastric mucosal protection by Famotidine," *Gastroenterology*, 97, pp. 944-949 (1989).

Dent et al., "Why proton pump inhibition should heal and protect against nonsteroidal anti-inflammatory drug ulcers," *Am. J. Med.*, 104, pp. 52S-55S (1998).

Ehsanullah et al., "Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine," *BMJ*, 297, pp. 1017-1021 (Oct. 1988).

Ekstrom et al., "Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy," *Scand. J. Gastroenterol.*, 31, pp. 753-758 (1996).

Ene et al., "A study of the inhibitory effects of SCH 28080 on gastric secretion in man," *Br. J. Pharmacol.*, 76, pp. 389-391 (1982).

Erlandsson et al., "Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a trisphenylcarbamoylcellulose-based stationary phase," *J. Chromatog.*, 532, pp. 305-319 (1990).

Feldman et al., "Effect on antacid on absorption on enteric-coated aspirin," *JAMA*, 227(6), pp. 660-661 (1974).

Florence et al., "Novel oral drug formulations their potential in modulating adverse effects," *Drug Safety*, 10(3), pp. 233-266 (1994).

Frank, et al., "Reduction of Indomethacin Induced Gastroduodenal

(56)

References Cited

OTHER PUBLICATIONS

- Gengo, et al., "Prevalence of Platelet Nonresponsiveness to Aspirin in Patients Treated for Secondary Stroke Prophylaxis and in Patients With Recurrent Ischemic Events," *J. Clin. Pharmacol.*, 48, pp. 335-343 (2008).
- Goldstein et al., "116 a single tablet multilayer formulation of enteric-coated naproxen coupled with non-enteric-coated omeprazole is associated with a significantly reduced incidence of gastric ulcers vs. enteric-coated naproxen: A prospective, randomized, double-blind study," *Gastroenterology*, Elsevier, Philadelphia, PA, 134(4), p. A-19 (Apr. 1, 2008).
- Goldstein, et al., "PN400 Significantly Improves Upper Gastrointestinal Tolerability Compared with Enteric-Coated Naproxen Alone in Patients Requiring Chronic NSAID Therapy: Results from Two Prospective, Randomized, Controlled Trials," POZEN Inc. sponsored study, 74th Annual Scientific Meeting of the American College of Gastroenterology, San Diego, CA (Oct. 27, 2009).
- Goldstein, et al., "PN400 Significantly Reduces the Incidence of Gastric Ulcers Compared With Enteric-Coated Naproxen in Patients Requiring Chronic NSAID Therapy Regardless of Low-Dose Aspirin Use: Results from Two Prospective, Randomized Controlled Trials," POZEN Inc. sponsored study, ACR/ARHP Mtg. (Oct. 16-21, 2009).
- Graham, et al., "Duodenal and Gastric Ulcer Prevention with Misoprostol in Arthritis Patients Taking NSAIDs," *Ann. Intern. Med.* 119(4):257-262 (Aug. 1993).
- Grosser et al., "Thromboxane Generation," in *Platelets*, Alan Michelson ed., Elsevier Science, pp. 565-574 (2007).
- Gurbel et al., "Abstract 4267: PA32520 (Single-tablet of enteric coated aspirin 325 mg + immediate-release omeprazole 20 mg): Aspirin therapy combining greater thromboxane suppression and lower upper gastrointestinal damage," *Circulation*, 118, p. S855 (2008).
- Hart, et al., "Aspirin Dosage and Thromboxane Synthesis in Patients with Vascular Disease," *Pharmacotherapy* 23(5):579-584 (2003).
- Hassan-Alin et al., "11651 lack of drug-drug interaction between esomeprazole and naproxen in healthy subjects," *Gastroenterology*, 124(4), Supp. 1, p. A541 (Apr. 2003).
- Hawkey et al., "Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs," *N. Engl. J. Med.*, 338, pp. 727-734 (1998).
- Hawkey et al., "Progress in prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions," *Am. J. Med.*, 104, pp. 67S-74S (1998).
- Office Action dated Jan. 5, 2012 issued for US Pub No. 2010/0062064.
- Office Action dated Jul. 30, 2012 issued for US Pub No. 2010/0062064.
- Office Action dated Apr. 22, 2004 issued for US Patent No. 6,926,907.
- Office Action dated Oct. 10, 2004 issued for US Patent No. 6,926,907.
- Notice of Allowance dated Mar. 29, 2005 issued for US Patent No. 6,926,907.
- Office Action dated Mar. 30, 2009 issued for US Patent No. 8,206,741.
- Office Action dated Nov. 19, 2009 issued for US Patent No. 8,206,741.
- Office Action dated Oct. 25, 2010 issued for US Patent No. 8,206,741.
- Office Action dated Jun. 16, 2011 issued for US Patent No. 8,206,741.
- Interview Summary dated Nov. 15, 2011 issued for US Patent No. 8,206,741.
- Interview Summary dated Mar. 7, 2012 issued for US Patent No. 8,206,741.
- Interview Summary dated Apr. 19, 2012 issued for US Patent No. 8,206,741.
- Notice of Allowance dated May 13, 2012 issued for US Patent No. ISR issued for WO 2010/151216, Sep. 20, 2010.
- Supplemental ISR issued for WO 2010/151216, Oct. 20, 2011.
- Written Opinion issued for WO 2010/151216, Sep. 20, 2010.
- U.S. Appl. No. 13/475,446, filed May 18, 2012.
- Preliminary Amendment for U.S. Appl. No. 13/475,446, filed May 18, 2012.
- Panara et al., "Effects of the novel anti-inflammatory compounds, N[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-inda none (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases," *British Journal of Pharmacology*, 116, pp. 2429-2434 (1995).
- Pang et al., "Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette review series)" *Drug Metabolism and Disposition*, 31(12), pp. 1507-1519 (2003).
- Patrono, et al., "Low-Dose Aspirin for the Prevention of Atherothrombosis," *New Eng. J. Med.*, 353, pp. 2373-2383 (2005).
- Petersen, "Doubts are raised on the safety of 2 popular arthritis drugs," *NY Times*, p. C1 (May 22, 2001).
- Pilbrant et al., "Development of an Oral Formulation of Omeprazole," *Scand. J. Gastroenterol.*, 20, Supp. 108, pp. 113-120 (1985).
- Pirmohamed et al., "Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients," *Br. Med. J.*, 329, pp. 15-19 (2004).
- Porter S.C., "Coating of Pharmaceutical Dosage Forms," in: A. Gennaro (Ed.), *Remington: the Science and Practice of Pharmacy*, 19th ed., pp. 1650-1651 (1995).
- Qureshi, et al., "Pharmacokinetics of Two Enteric-Coated Ketoprofen Products in Humans with or Coadministration of Omeprazole and Comparison with Dissolution Findings," *Pharmaceutical Research*, 11(11), pp. 1669-1672 (1994).
- Raskin, et al., "Misoprostol Dosage in the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Gastric and Duodenal Ulcers: A Comparison of Three Regimens," *Ann. Intern. Med.*, 123(5), pp. 344-350 (Sep. 1995).
- Richardson et al., "Proton pump inhibitors, pharmacology and rationale for use in gastrointestinal disorders," *Drugs*, 56 (3), pp. 307-335 (1998).
- Robinson, et al., "Effects of Ranitidine Gastroduodenal Mucosal Damage Induced by Nonsteroidal Anti-inflammatory Drugs," *Dig. Dis. Sci.*, 34(3), pp. 424-428 (Mar. 1989).
- Roth, et al., "Cimetidine Therapy in Nonsteroidal Anti-inflammatory Drug Gastropathy: Double-blind Long-term Evaluation," *Arch. Intern. Med.*, 147, pp. 1798-1801 (1987).
- Rubinstein, "Gastrointestinal anatomy physiology and permeation pathways," *Enhancement in Drug Discovery*, CRC Press, pp. 3-35 (2007).
- Sangiah et al., "Effects of misoprostol and omeprazole on basal gastric pH and free acid content in horses," *Res. Vet. Sci.*, 47(3), pp. 350-354 (1989).
- Savarino et al., "Effect of one-month treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients," *Digestive Diseases and Sciences*, 43, pp. 459-463 (1998).
- Scarpignato et al., *Gastroenterology International*; pp. 186-215 (1999).
- Scheiman et al., "NSAID-induced peptic ulcer disease: a critical review of pathogenesis and management," *Dig. Dis.*, 12, pp. 210-222 (1994).
- Scheiman et al., "Omeprazole ameliorates aspirin-induced gastroduodenal injury," *Digestive Diseases and Sciences*, 39(1), pp. 97-103 (1994).
- Scheiman, *Seminars in Arthritis and Rheumatism*, pp. 201-210 (1992).
- Scott and Sundell, "Inhibition of H+K+ ATPase by SCH 28080 and SCH 32651," *European Journal of Pharmacology*, 112, pp. 268-270 (1985).
- Seitz et al., "Tablet coating," in *The theory and practice of industrial pharmacy*, Lachman et al. eds., Lea and Febiger, pp. 346-373 (1986).

(56)

References Cited

OTHER PUBLICATIONS

Hawkey et al., "Prophylaxis of aspirin-induced gastric mucosal bleeding with ranitidine," *Aliment. Pharmacol. Therap.*, 2, pp. 245-252 (1988).

Hawkey et al., *Scandinavian J. Gastroenterology*, pp. 124-127 (1996)

Handbook of Pharmaceutical Excipients, 5th Edition (2006).

Hawkey et al., *Scandinavian J. Gastroenterology*, pp. 170-173 (1986).

Hawkins & Hanks, *J. Pain and Symptom Management*, pp. 140-151 (2000).

Helander et al., "Structure and function of rat parietal cells during treatment with omeprazole, SCH 28080, SCH 32651, or ranitidine," *Scan. J. Gastroenterol.*, 25, pp. 799-809 (1990).

Histamine H2 antagonist information on drugs.com website, downloaded Feb. 20, 2012.

Hogan et al., "Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta," *Can. Med. Assoc.*, 151(3), pp. 315-322 (1994).

Howden, "Clinical Pharmacology of Omeprazole," *Clin. Pharmacokinet.*, 20(1), pp. 38-49 (1991).

Ife et al., "Reversible inhibitors of the Gastric (H.sup.+ /K.sup.+)-ATPase. 3. 3-Substituted-4-(phenylamino)quinolines," *J. Med. Chem.*, 35, pp. 3413-3422 (1992).

Jiranek, et al., "Misoprostol Reduces Gastrointestinal Injury From One Week of Aspirin: An Endoscopic Study," *Gastroenterology*, 96, pp. 656-661 (1989).

Katz et al., "Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole," *Aliment. Pharmacol. Ther.*, 14, pp. 709-714 (2000).

Keeling et al., "SK&F 96067 is a reversible, lumenally acting inhibitor of the gastric (H.sup.+ +K.sup.+)-ATPase," *Biochemical Pharmacology*, 42(1), pp. 123-130 (1991).

Kephart et al., "Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia's senior population," *Clin. Ther.*, 17, pp. 1159-1173 (1995).

Kimmey et al., "Role of H2-receptor blockers in the prevention of gastric injury resulting from nonsteroidal anti-inflammatory agents," *Am. J. Med.*, 84, pp. 49-52 (1988).

Kitchingman, et al., "Enhanced Gastric Mucosal Bleeding with Doses of Aspirin Used for Prophylaxis and Its Reduction by Ranitidine," *Br. J. Clin. Pharmacol.*, 28, pp. 581-585 (1989).

Konturek et al., "Effects of omeprazole, a substituted benzimidazole, on gastrointestinal secretions, serum gastrin, and gastric mucosal blood flow in dogs," *Gastroenterology*, 86(1), pp. 71-77 (1984).

Lad et al., "Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression," *Can. J. Gastroenterol.*, 13, pp. 135-142 (1999).

Lanas, A. "Prevention of aspirin-induced gastroduodenal damage: *H. pylori* infection eradication versus proton pump inhibitors or both," *Digestive and Liver Disease*, 36, pp. 655-657 (2004).

Lanza, et al., "A Double-Blind Placebo-Controlled Comparison of the efficacy and Safety of 50, 100, and 200 ug of Misoprostol QID in the Prevention of Ibuprofen-Induced Gastric and Duodenal Mucosal Lesions and Symptoms," *Am. J. Gastroenterol.*, 84(6), pp. 633-636 (1989).

Lanza, et al., "Double-Blind, Placebo-Controlled Endoscopic Comparison of the Mucosal Protective Effects of Misoprostol Versus Cimetidine on Tolmetin-Induced Mucosal Injury to the Stomach and Duodenum," *Gastroenterology*, 95, pp. 289-294 (1988).

Larsson et al., "Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo," *Scand J Gastroenterol Suppl.*, 108, pp. 23-35 (1985).

Lee et al., "Omeprazole prevents indomethacin-induced gastric ulcers in rabbits," *Aliment. Pharmacol. Ther.*, 10, pp. 571-576 (1996).

Leese, et al., "Effects of Celecoxib, a Novel Cyclooxygenase-2 Inhibitor, on Platelet Function in Healthy Adults: A Randomized, Controlled Trial," *J. Clin. Pharmacol.*, 40, pp. 124-132 (2000).

Leonards et al., "Reduction or prevention of aspirin-induced occult

Lichtenberger et al., "Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats," *Gastroenterology*, 111, pp. 990-995 (1996).

Lin and Lu, "Role of pharmacokinetics and metabolism in drug discovery and development," *Pharmacological Reviews*, 49(4), pp. 403-449 (1997).

Maggi et al., *Int. J. Pharm.*, pp. 173-179 (1993).

Mason et al., "Kinetics of aspirin, salicylic acid, and salicylic acid following oral administration of aspirin as a tablet and two buffered solutions," *J. Pharmaceutical Sciences*, 70(3), pp. 262-265 (1981).

Mattson et al., "Omeprazole provides protection against experimentally induced gastric mucosal lesions," *Eur. J. Pharmacol.*, 91, pp. 111-114 (1983).

McKeage et al., "Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults," *Drugs*, 68(11), pp. 1571-1607 (2008).

Miner et al., "Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed dose combination of PN400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric coated esomeprazole 20 mg: a randomized, open-label, phase 1 study in healthy volunteers," *Alimentary pharmacology and therapeutics*, 32, pp. 414-424, table 1 (2010).

Miner et al., "T1969 gastric acid suppression with PN400, a single-tablet, multilayer, fixed-dose formulation combining an immediate-release esomeprazole layer and an enteric-coated naproxen core," *Gastroenterology*, Elsevier, Philadelphia, PA, 136(5), p. A-611 (May 1, 2009).

Miner et al., "T1972 Pharmacokinetics of Naproxen and Esomeprazole in PN400, a single-tablet, multilayer formulation of enteric-coated Naproxen coupled with immediate-release Esomeprazole," *Gastroenterology*, Elsevier, Philadelphia, PA, 136(5), p. A-612 (May 1, 2009).

Morgner et al., "Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers," *Expert opinion on pharmacotherapeutics*, 8(7), pp. 975-988 (2007).

Morris, et al., "Gastric Cytoprotection Is Secondary to Increased Mucosal Fluid Secretion: A Study of Six Cytoprotective Agents in the Rat," *J. Clin. Gastroenterol.*, 27, Suppl. 1, pp. S53-S63 (1998).

Morrison et al., "The optimal analgesic dose of rofecoxib: overview of six randomized controlled trials," *JADA*, 131, pp. 1729-1737 (2000).

Muller English translation—Muller, et al., "Untersuchungen zur Schutzwirkung von Lansoprazol auf die menschliche Magenschleimhaut gegenüber niedrig dosierter Acetylsalicylsäure," *Arzneimittel Forschung*, 47, pp. 758-760 (1997).

Muller English translation—Muller, et al., "Verbesserung der gastroduodenalen Vertraglichkeit von Azetylsalicylsäure durch Ranitidin," *Arzneimittel-Forschung/Drug Res.*, 41(1), pp. 638-639 (1991).

Muller, et al., "Untersuchungen zur Schutzwirkung von Lansoprazol auf die menschliche Magenschleimhaut gegenüber niedrig dosierter Acetylsalicylsäure," *Arzneimittel Forschung*, 47, pp. 758-760 (1997).

Muller, et al., "Verbesserung der gastroduodenalen Vertraglichkeit von Azetylsalicylsäure durch Ranitidin," *Arzneimittel-Forschung/Drug Res.*, 41(1), pp. 638-639 (1991).

Naesdal, et al., "Gastro-Duodenal Protection in an Era of Cyclooxygenase-2-Selective Nonsteroidal Anti-Inflammatory Drugs," *European Journal of Gastroenterology & Hepatology*, 13(12), pp. 1401-1406 (2001).

Naprosyn EC Label, Roche (1999).

Nefesoglu, et al., "Interaction of Omeprazole with Enteric-Coated Salicylate Tablets," *International Journal of Clinical Pharmacology and Therapeutics*, 36(10), pp. 549-553 (1998).

Neuvonen et al., "Enhancement of drug absorption of antacids," *Clin. Pharmacokinet.*, 27(2), pp. 120-128 (1994).

Oddsson et al., "Endoscopic findings in the stomach and duodenum after treatment with enteric-coated and plain naproxen tablets in healthy subjects," *Scand. J. Gastroenterol.*, 25, pp. 231-234 (1990).

Oddsson, et al., "Comparison between Ranitidine and Omeprazole

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.